Gianni Virgili1, Mariacristina Parravano2, Gemma Gatta3, Riccardo Capocaccia4, Cinzia Mazzini1, Sandra Mallone5, Laura Botta3. 1. AOU Careggi, Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Firenze, Florence, Italy. 2. Ophthalmology, IRCCS-Fondazione Bietti, Rome, Italy. 3. Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Rome, Italy. 5. Istituto Superiore di Sanità, Rome, Italy.
Abstract
Importance: Conjunctival melanoma (CM) is a rare ocular tumor. Estimates of incidence and survival of patients with CM are important to researchers and policy makers. Objective: To estimate incidence and survival of patients with CM in Europe. Design, Setting, and Participants: This population-based cohort study used data from 41 European cancer registries adhering to the RARECAREnet project. All individuals diagnosed as having malignant CM from January 1995 to December 2007 coded according to the International Classification of Diseases for Oncology, Third Edition codes C69.0 (conjunctiva) and 8720-8780 (melanoma) were included. Analysis began March 2019. Main Outcomes and Measures: Trend estimates for incidence and for 5-year relative survival (the ratio of the measured survival of patients to the expected survival in the general population for the same country, age, sex, and calendar year). Crude, age-standardized, and bayesian incidence rates were calculated. Five-year relative survival was calculated by the Ederer II method with the cohort and period approach. Results: A total of 724 patients 15 years or older (512 [70.7%] were 55 years or older; 366 [50.6%] were female) were analyzed with an overall crude incidence of CM (per 1 000 000 person/y) of 0.46 (95% CI, 0.42-0.49). Crude incidence was similar in men and women (0.48; 95% CI, 0.44-0.54 and 0.46; 95% CI, 0.41-0.51, respectively) and increased with age. Age-standardized incidence increased over time only in men and was the highest in Norway and the Netherlands (more than 0.70). Only 1 case in 14 years was estimated to occur in Iceland vs about 20 cases per year in large countries such as France and Germany. Percentage of 5-year survival (83.5 overall; 95% CI, 78.6-87.3) was not different between adult and elderly patients but showed large geographical disparities across European regions (range, 66-89) and improved markedly in male patients (from 76 in 1995-1998 to 86 in 2003-2007, with a difference of 10.2 [95% CI, 1.3-19.2]; P < .05) becoming similar to that of women in the last period. Conclusions and Relevance: Although these data are only available through 2007 and based on registries not uniformly covering the European population, the study provides the first Europe-wide estimates of the incidence and relative survival of patients with CM using population-based data. Geographical differences in survival indicate room for outcome improvement in Southern, Northern, and Eastern European countries.
Importance: Conjunctival melanoma (CM) is a rare ocular tumor. Estimates of incidence and survival of patients with CM are important to researchers and policy makers. Objective: To estimate incidence and survival of patients with CM in Europe. Design, Setting, and Participants: This population-based cohort study used data from 41 European cancer registries adhering to the RARECAREnet project. All individuals diagnosed as having malignant CM from January 1995 to December 2007 coded according to the International Classification of Diseases for Oncology, Third Edition codes C69.0 (conjunctiva) and 8720-8780 (melanoma) were included. Analysis began March 2019. Main Outcomes and Measures: Trend estimates for incidence and for 5-year relative survival (the ratio of the measured survival of patients to the expected survival in the general population for the same country, age, sex, and calendar year). Crude, age-standardized, and bayesian incidence rates were calculated. Five-year relative survival was calculated by the Ederer II method with the cohort and period approach. Results: A total of 724 patients 15 years or older (512 [70.7%] were 55 years or older; 366 [50.6%] were female) were analyzed with an overall crude incidence of CM (per 1 000 000 person/y) of 0.46 (95% CI, 0.42-0.49). Crude incidence was similar in men and women (0.48; 95% CI, 0.44-0.54 and 0.46; 95% CI, 0.41-0.51, respectively) and increased with age. Age-standardized incidence increased over time only in men and was the highest in Norway and the Netherlands (more than 0.70). Only 1 case in 14 years was estimated to occur in Iceland vs about 20 cases per year in large countries such as France and Germany. Percentage of 5-year survival (83.5 overall; 95% CI, 78.6-87.3) was not different between adult and elderly patients but showed large geographical disparities across European regions (range, 66-89) and improved markedly in male patients (from 76 in 1995-1998 to 86 in 2003-2007, with a difference of 10.2 [95% CI, 1.3-19.2]; P < .05) becoming similar to that of women in the last period. Conclusions and Relevance: Although these data are only available through 2007 and based on registries not uniformly covering the European population, the study provides the first Europe-wide estimates of the incidence and relative survival of patients with CM using population-based data. Geographical differences in survival indicate room for outcome improvement in Southern, Northern, and Eastern European countries.
Authors: Carol L Shields; Jeremy S Markowitz; Irina Belinsky; Hal Schwartzstein; Nina S George; Sara E Lally; Arman Mashayekhi; Jerry A Shields Journal: Ophthalmology Date: 2010-08-17 Impact factor: 12.079
Authors: Ann-Cathrine Larsen; Christina M Dahmcke; Christina Dahl; Volkert D Siersma; Peter B Toft; Sarah E Coupland; Jan U Prause; Per Guldberg; Steffen Heegaard Journal: JAMA Ophthalmol Date: 2015-11 Impact factor: 7.389
Authors: Paolo Baili; Francesca Di Salvo; Rafael Marcos-Gragera; Sabine Siesling; Sandra Mallone; Mariano Santaquilani; Andrea Micheli; Roberto Lillini; Silvia Francisci Journal: Eur J Cancer Date: 2015-09-26 Impact factor: 9.162
Authors: Laura Botta; Riccardo Capocaccia; Annalisa Trama; Christian Herrmann; Diego Salmerón; Roberta De Angelis; Sandra Mallone; Ettore Bidoli; Rafael Marcos-Gragera; Dorota Dudek-Godeau; Gemma Gatta; Ramon Cleries Journal: Cancer Epidemiol Date: 2018-04-21 Impact factor: 2.984
Authors: Puneet Jain; Paul T Finger; Bertil Damato; Sarah E Coupland; Heinrich Heimann; Nihal Kenawy; Niels J Brouwer; Marina Marinkovic; Sjoerd G Van Duinen; Jean Pierre Caujolle; Celia Maschi; Stefan Seregard; David Pelayes; Martin Folgar; Yacoub A Yousef; Hatem Krema; Brenda Gallie; Alberto Calle-Vasquez Journal: JAMA Ophthalmol Date: 2019-08-01 Impact factor: 7.389